0001144204-18-003268.txt : 20180123 0001144204-18-003268.hdr.sgml : 20180123 20180123152443 ACCESSION NUMBER: 0001144204-18-003268 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180123 DATE AS OF CHANGE: 20180123 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Capstone Therapeutics Corp. CENTRAL INDEX KEY: 0000887151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860585310 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-42745 FILM NUMBER: 18542222 BUSINESS ADDRESS: STREET 1: 1275 WEST WASHINGTON STREET STREET 2: SUITE 101 CITY: TEMPE STATE: AZ ZIP: 85281 BUSINESS PHONE: 6022865520 MAIL ADDRESS: STREET 1: 1275 WEST WASHINGTON STREET STREET 2: SUITE 101 CITY: TEMPE STATE: AZ ZIP: 85281 FORMER COMPANY: FORMER CONFORMED NAME: ORTHOLOGIC CORP DATE OF NAME CHANGE: 19940211 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SUBIN NEIL S CENTRAL INDEX KEY: 0001201333 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 8 PALM COURT CITY: SEWALLS POINT STATE: FL ZIP: 34996 SC 13G 1 tv483738_sc13g.htm SC 13G

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. __)*

 

Capstone Therapeutics Corp.
(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

  14068E109  
  (CUSIP Number)  
 

 

January 12, 2018

  
  (Date of Event which Requires Filing of this Statement)  

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

þ Rule 13d-1(c)

¨ Rule 13d-1(d)

 

Page 1 of 5

 

 

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

SCHEDULE 13G

 

CUSIP No. 14068E109   Page 2 of 5 Pages

 

1

NAME OF REPORTING PERSON

 

Neil S. Subin  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)   ¨
  (b)   ¨
3 SEC USE ONLY
 
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
         

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 5 SOLE VOTING POWER
7,567,078
6 SHARED VOTING POWER
90,344
7 SOLE DISPOSITIVE POWER
7,567,078
8 SHARED DISPOSITIVE POWER
90,344

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,657,422

 

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.1%1
12 TYPE OF REPORTING PERSON
IN-OO**

 

** See Item 4.

 

 

1 The percentage reported in this Schedule 13G is based upon 54,385,411 shares of Common Stock outstanding according to the Form 10-Q filed by the Issuer on November 13, 2017. 

 

 Page 3 of 5

  

Item 1(a). Name of Issuer: Capstone Therapeutics Corp.
     
Item 1(b). Address of Issuers’ Principal Executive Offices: 1275 W. Washington Street
  Suite 104
  Tempe, AZ 85281
     
Item 2(a). Name of Person Filing: Neil S. Subin
     
Item 2(b). Address of Principal Business Office or, if None, Residence: 3300 South Dixie Highway
    Suite 1-365
    West Palm Beach, Florida 33405
     
Item 2(c). Citizenship: U.S.A.
     
Item 2(d). Title of Class of Securities: Common Stock
     
Item 2(e). CUSIP Number: 14068E109

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b) OR 13d-2(b) or (c), CHECK WHETHER THE PERSON FILING IS A:
   
  Not Applicable, this statement is filed pursuant to 13d-1(c)
   
Item 4. OWNERSHIP:  This filing is being made to report that Mr. Neil S. Subin has succeeded to the position of President and Manager of MILFAM LLC, which serves as manager, general partner, or investment advisor of a number of entities formerly managed or advised by the late Lloyd I. Miller, III. Mr. Subin also serves as trustee of a number of Miller family trusts.

 

  (a) 7,657,422
     
  (b) 14.1%
     
  (c) (i) sole voting power:  7,567,078
     
    (ii) shared voting power: 90,344
     
    (iii) sole dispositive power: 7,567,078
     
    (iv) shared dispositive power: 90,344

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
   
  Not Applicable
   
Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
   
  Persons other than Neil S. Subin have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the reported securities, including Lloyd I. Miller, III Trust A-4, and MBM-Trust A-4.

 

 

 Page 4 of 5

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
   
  Not Applicable
   
Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
   
  Not Applicable
   
Item 9. NOTICE OF DISSOLUTION OF GROUP:
   
  Not Applicable
   
Item 10. CERTIFICATION:
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 Page 5 of 5

  

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: January 23, 2018 /s/ Neil S. Subin
   Neil S. Subin